Increasing affordability and patient access to life saving and life extending therapies.
Developing a diverse portfolio of clinically identical biosimilars for patients, globally.
We value affordable access to healthcare, the quality and integrity of our science, and a strong patient focus.
Increasing affordability and patient access to life saving and life extending therapies.
Developing a diverse portfolio of clinically identical biosimilars for patients, globally.
We value affordable access to healthcare, the quality and integrity of our science, and a strong patient focus.
NeuClone has completed dosing of subjects in a Phase I clinical trial with its Herceptin® (trastuzumab) biosimilar, NeuCeptin
NeuClone representatives attend the 37th Annual J.P. Morgan Healthcare Conference
NeuClone features in BioWorld: Interview with Dr Noelle Sunstrom
NeuClone Announces its Sixth Biosimilar Candidate Perjeta® (Pertuzumab) for Use in Combination Therapy with Herceptin® (Trastuzumab)
NeuClone Announces First Human Dose of Herceptin® (Trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
NeuClone Announces Preclinical Results for Stelara (ustekinumab) Biosimilar Candidate
NeuClone discloses details of its fifth product: a biosimilar candidate for Prolia®/XGEVA®
NeuClone attends the 23rd International Partnering Conference BIO-Europe
NeuClone presents at the 25th ESACT Meeting
NeuClone attends the 35th Annual J.P. Morgan Healthcare Conference
NeuClone presents at the 22nd Annual BIO-Europe Conference
US patent granted for NeuCHO®, NeuClone’s robust cell expression system
Dr. Angelo Perani presents at the 12th annual Cell Line Development and Engineering conference
Dr. Russell Howard, John Oksinski and Dr. Noelle Sunstrom attend the BIO International Convention
Dr. Noelle Sunstrom attends Cell Culture Engineering XV
The Hon Sussan Ley MP, Minister of Health, officially opens NeuClone’s new biomanufacturing facilities
